Job details
Facility undisclosed
Required Qualifications MD, MD
The University of Alabama at Birmingham Portal | Heersink School of Medicine-Open Rank Division Director-Radiology (Molecular Imaging & Therapeutics ) Skip to Main Content (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-P7PM9Z7'); .header-inner { min-height: 0px; max-height: 100px; } Toggle navigation Home Search Jobs Log In /Create Account Help FAQs .navBG ul#navLinks > li > a, .navBG ul#customnav > li > a { background-color: #FAFDF5; color: #1E6B52; } UAB Home UAB Human Resources Benefits About Birmingham Heersink School of Medicine-Open Rank Division Director-Radiology (Molecular Imaging & Therapeutics ) Bookmark this Requisition Print Preview | Apply for this Job Posting Details Position Information School/College School of Medicine Title Heersink School of Medicine-Open Rank Division Director-Radiology (Molecular Imaging & Therapeutics ) Assignment Category Full-Time Rank Open Rank Tenure Status Open Tenure Payroll Status Faculty 12 Job Description The Department of Radiology, a clinical department of the School of Medicine at the University of Alabama at Birmingham ( UAB ), invites applications from highly qualified individuals for tenure-earning and tenured positions at the rank of Associate Professor or Professor, commensurate with experience and qualifications. We seek highly accomplished physician-scientists with strong nuclear medicine–related clinical and research interests, including molecular imaging and theranostics, and a demonstrated commitment to collaborative, interdisciplinary scholarship and leadership. Qualified candidates must hold an MD or MD/PhD degree and possess a proven ability to work effectively within multidisciplinary clinical and research teams. The Division of Molecular Imaging & Therapeutics (MI&T) at UAB provides comprehensive clinical nuclear medicine services supporting UAB Hospitals and affiliated clinical programs. The division delivers diagnostic and therapeutic molecular imaging services across oncology, neurology, cardiology, and other subspecialties, with a growing emphasis on theranostics and radiopharmaceutical therapy. Clinical services include PET /CT, SPECT /CT, targeted radiotracer imaging, and radionuclide therapies, delivered in close collaboration with multidisciplinary clinical teams. The division currently comprises a multidisciplinary group of nine clinical and research faculty, supported by experienced technologists, physicists, radiochemists, and administrative staff. MI&T plays a central role in patient care within the O’Neal Comprehensive Cancer Center and collaborates closely with neurology, cardiology, oncology, and surgical services across the health system. The Division Director and Section Chief will provide strategic and operational leadership for the MI&T clinical enterprise. Responsibilities include oversight of clinical operations and quality, faculty recruitment and development, programmatic growth of diagnostic and therapeutic services, coordination with hospital and departmental leadership, and stewardship of divisional resources. The Division Director is expected to foster a strong clinical culture while supporting and enabling faculty research activities. While the Division Director may also be an active investigator, personal research productivity is not required, provided there is demonstrated commitment to supporting and advancing faculty. UAB Radiology has a rapidly expanding health system with strengths in molecular imaging and therapeutics, supported by robust infrastructure including an ACSI TR24 cyclotron, GE Signa TOF PET / MRI , GE Omni 32 PET /CT, and small animal PET /CT, SPECT /CT, MRI , and other modalities. Current initiatives include finalizing agreements for the Omni Legend 128 and Omni Legend 24 cardiac PET systems, as well as the recent acquisition of the StarGuide SPECT /CT system. These investments enhance imaging capabilities, increase operational capacity, and strengthen the department’s position as a leader in advanced molecular imaging and nuclear medicine. Future directions include expansion of clinical and investigational theranostics programs, increased clinical trial activity, and growth in disease‑focused molecular imaging services.
Measures how much useful job information is disclosed — not whether the job is good or bad.
These details matter when comparing physician jobs.
UAB Heersink School of Medicine